STAT3-induced ZBED3-AS1 promotes the malignant phenotypes of melanoma cells by activating PI3K/AKT signaling pathway.

Publication date: Jul 09, 2021

Melanoma is considered as the most frequent primary malignancy occurring in skin. Accumulating studies have suggested that long non-coding RNAs (lncRNAs) play critical parts in multiple cancers. In this study, we explored the molecular mechanism of ZBED3 antisense RNA 1 (ZBED3-AS1) in melanoma. We observed that ZBED3-AS1 expression was remarkably up-regulated in melanoma tissues, and high ZBED3-AS1 level was linked to unsatisfactory survival of melanoma patients. Then, we discovered that ZBED3-AS1 was overexpressed in melanoma cells compared with human epidermal melanocytes. In addition, loss-of-function assays verified that ZBED3-AS1 knockdown restrained cell proliferation, migration, epithelial-mesenchymal transition (EMT) and stemness in melanoma. In addition, signal transducer and activator of transcription 3 (STAT3), which also showed tumor-facilitating functions in melanoma, was confirmed as a transcriptional activator of ZBED3-AS1. Moreover, ZBED3-AS1 enhanced the expression of AT-rich interaction domain 4B (ARID4B) through sequestering miR-381-3p. Importantly, we further confirmed that ZBED3-AS1 promoted the malignant progression of melanoma by regulating miR-381-3p/ARID4B axis to activate the phosphatidylinositol 3-kinase/AKT serine/threonine kinase (PI3K/AKT) signaling pathway. In a word, our research might provide a novel therapeutic target for melanoma.

Concepts Keywords
Arid4b Branches of biology
Migration Signal transduction
Phosphatidylinositol Protein kinases
Rich Cancer
Tumor Melanoma
Akt/PKB signaling pathway
Phosphoinositide 3-kinase
Protein kinase B


Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH malignancy
drug DRUGBANK Serine
drug DRUGBANK L-Threonine

Leave a Comment

Your email address will not be published. Required fields are marked *